Novel Pharmacological Probes Targeting Exchange Proteins Activated by cAMP (EPAC)
针对 cAMP 激活的交换蛋白的新型药理学探针 (EPAC)
基本信息
- 批准号:8482964
- 负责人:
- 金额:$ 49.11万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-04-01 至 2016-03-31
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs DiseaseAmyloidAnimal ModelAutistic DisorderBindingBiochemicalBiological AssayBiological ProcessBiologyCell physiologyCellsChemicalsCollaborationsCyclic AMPCyclic AMP ReceptorsCyclic AMP-Dependent Protein KinasesDataDevelopmentDiabetes MellitusDiseaseDockingEukaryotic CellFamilyFibrosisGrowthGuanine Nucleotide Exchange FactorsHeart HypertrophyImmune responseInflammationIntracellular Second MessengerKnowledgeLaboratoriesLeadLeptinLibrariesLinkMalignant NeoplasmsMalignant neoplasm of pancreasMediatingMedicalMolecularMuscle CellsNeoplasm MetastasisObesityPathway interactionsPharmaceutical ChemistryPharmaceutical PreparationsPhysiologicalPlayPrincipal InvestigatorProcessPropertyProteinsResearchRoleSecond Messenger SystemsSignal PathwaySignal TransductionSignaling ProteinSpecificityStructure-Activity RelationshipSynaptic TransmissionTherapeuticTissuesaxon regenerationbasecell motilitydesigndisease mechanisms studyhigh throughput screeninghuman diseasein vitro Assayin vivoinhibitor/antagonistinsulin secretionnovelprocess optimizationpublic health relevanceresponsescreeningsmall moleculetherapeutic target
项目摘要
DESCRIPTION (provided by applicant): This is an R01 application in response to FOA PAR-12-060 "Solicitation of Validated Hits for the Discovery of in vivo Chemical Probe (R01)". cAMP-mediated cell signaling regulates a myriad of important biological processes and plays important roles in the development of many human diseases. In eukaryotic cells, the effects of cAMP are mainly transduced by two groups of intracellular cAMP receptors, the classic protein kinase A/cAMP-dependent protein kinase (PKA/cAPK) and a new family of more recently discovered exchange proteins directly activated by cAMP/cAMP-regulated guanine nucleotide exchange factor (EPACs/cAMP-GEFs). One of the major challenges within the research field is the lack of EPAC specific antagonists for interrogating the biological functions of EPACs in physiological setting and for understanding of disease mechanisms in which EPACs are implicated. To bridge this gap, we have identified and validated several novel, first-in-class small chemical antagonists specific for EPACs. In the present proposal, we will build on the validated hits discovered in our laboratory as the lead candidates and design, synthesize and evaluate more potent and specific EPAC specific probes. Optimized EPAC chemical probes that effectively inhibit EPAC signaling in biochemical and cell-based assays will be analyzed in vivo in animal models to identify potential target molecules for development of EPAC-based therapeutics. The proposed studies build upon an ongoing, proven productive collaboration between two principal investigators with extensive complimentary expertise in EPAC/cAMP biology and medicinal chemistry, respectively. The interdisciplinary perspectives, new chemical entities and emerging medical importance of EPAC will lead to the discovery of a new class of in vivo chemical probes that can be used in studying disease mechanisms and treatments related to EPAC signaling.
描述(由申请人提供):这是响应 FOA PAR-12-060“体内化学探针发现的验证命中征集(R01)”的 R01 申请。 cAMP 介导的细胞信号传导调节许多重要的生物过程,并在许多人类疾病的发展中发挥重要作用。在真核细胞中,cAMP 的作用主要由两组细胞内 cAMP 受体转导,即经典蛋白激酶 A/cAMP 依赖性蛋白激酶 (PKA/cAPK) 和最近发现的由 cAMP/直接激活的新交换蛋白家族。 cAMP 调节的鸟嘌呤核苷酸交换因子 (EPAC/cAMP-GEF)。研究领域的主要挑战之一是缺乏 EPAC 特异性拮抗剂来探究 EPAC 在生理环境中的生物学功能以及了解 EPAC 所涉及的疾病机制。为了弥补这一差距,我们鉴定并验证了几种针对 EPAC 的新型、一流的小化学拮抗剂。在目前的提案中,我们将以我们实验室发现的经过验证的命中为主要候选者,设计、合成和评估更有效和更具体的 EPAC 特异性探针。优化的 EPAC 化学探针可在生化和细胞检测中有效抑制 EPAC 信号传导,并将在动物模型体内进行分析,以确定用于开发基于 EPAC 的疗法的潜在靶分子。拟议的研究建立在两位分别在 EPAC/cAMP 生物学和药物化学领域拥有广泛互补专业知识的主要研究人员之间正在进行的、经过验证的富有成效的合作的基础上。 EPAC 的跨学科视角、新化学实体和新兴的医学重要性将导致发现一类新型体内化学探针,可用于研究与 EPAC 信号传导相关的疾病机制和治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
XIAODONG CHENG其他文献
XIAODONG CHENG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('XIAODONG CHENG', 18)}}的其他基金
Significance of Epac signaling in renal Na+ handling and hypertension
Epac 信号在肾钠处理和高血压中的意义
- 批准号:
10864073 - 财政年份:2023
- 资助金额:
$ 49.11万 - 项目类别:
Epac1 as a novel therapeutic target for diabetic retinopathy
Epac1作为糖尿病视网膜病变的新型治疗靶点
- 批准号:
10689112 - 财政年份:2022
- 资助金额:
$ 49.11万 - 项目类别:
Exchange Protein directly Activated by cAMP (EPAC): Structure, Function and Therapeutics
cAMP 直接激活的交换蛋白 (EPAC):结构、功能和治疗
- 批准号:
10198941 - 财政年份:2017
- 资助金额:
$ 49.11万 - 项目类别:
Preclinical Development of Novel Rickettsiosis Therapeutics Targeting EPAC1
针对 EPAC1 的立克次体病新型疗法的临床前开发
- 批准号:
9250048 - 财政年份:2014
- 资助金额:
$ 49.11万 - 项目类别:
Preclinical Development of Novel Rickettsiosis Therapeutics Targeting EPAC1
针对 EPAC1 的立克次体病新型疗法的临床前开发
- 批准号:
9038248 - 财政年份:2014
- 资助金额:
$ 49.11万 - 项目类别:
Preclinical Development of Novel Rickettsiosis Therapeutics Targeting EPAC1
针对 EPAC1 的立克次体病新型疗法的临床前开发
- 批准号:
8694342 - 财政年份:2014
- 资助金额:
$ 49.11万 - 项目类别:
High throughput assay for novel pharmacological probes targeting cAMP signaling
针对 cAMP 信号传导的新型药理学探针的高通量测定
- 批准号:
8477859 - 财政年份:2010
- 资助金额:
$ 49.11万 - 项目类别:
High throughput assay for novel pharmacological probes targeting cAMP signaling
针对 cAMP 信号传导的新型药理学探针的高通量测定
- 批准号:
7991500 - 财政年份:2010
- 资助金额:
$ 49.11万 - 项目类别:
Genetic Screening:Oncogene RAS-Based Inhibi*(RMI)
基因筛查:Oncogene RAS-Based Inhibi*(RMI)
- 批准号:
7058055 - 财政年份:2005
- 资助金额:
$ 49.11万 - 项目类别:
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor
Epac/cAMP-GEF,一种新型细胞内 cAMP 受体
- 批准号:
6743684 - 财政年份:2003
- 资助金额:
$ 49.11万 - 项目类别:
相似国自然基金
靶向干预CD33/Aβ相互作用改善小胶质细胞功能延缓AD病理进程
- 批准号:81901072
- 批准年份:2019
- 资助金额:20.5 万元
- 项目类别:青年科学基金项目
Pcdh-γC5介导的神经突触异常参与AD疾病发生的分子机制研究
- 批准号:81870845
- 批准年份:2018
- 资助金额:56.0 万元
- 项目类别:面上项目
阿尔茨海默病疾病进程中Aβ种子的作用变化及机制研究
- 批准号:81701059
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
基于自发性糖尿病老年食蟹猴阿尔茨海默病模型的建立和评估
- 批准号:31472056
- 批准年份:2014
- 资助金额:88.0 万元
- 项目类别:面上项目
EndophilinB1对APP及A-beta的调控作用在阿尔茨海默病中的机制性研究
- 批准号:81171017
- 批准年份:2011
- 资助金额:55.0 万元
- 项目类别:面上项目
相似海外基金
Fluency from Flesh to Filament: Collation, Representation, and Analysis of Multi-Scale Neuroimaging data to Characterize and Diagnose Alzheimer's Disease
从肉体到细丝的流畅性:多尺度神经影像数据的整理、表示和分析,以表征和诊断阿尔茨海默病
- 批准号:
10462257 - 财政年份:2023
- 资助金额:
$ 49.11万 - 项目类别:
Project 3: 3-D Molecular Atlas of cerebral amyloid angiopathy in the aging brain with and without co-pathology
项目 3:有或没有共同病理的衰老大脑中脑淀粉样血管病的 3-D 分子图谱
- 批准号:
10555899 - 财政年份:2023
- 资助金额:
$ 49.11万 - 项目类别:
Project 2: Biomarker Analysis, Non-Genetic Risk Factors, and Their Genetic Interactions
项目 2:生物标志物分析、非遗传风险因素及其遗传相互作用
- 批准号:
10555697 - 财政年份:2023
- 资助金额:
$ 49.11万 - 项目类别:
Centrally-linked longitudinal peripheral biomarkers of AD in multi-ethnic populations
多种族人群中 AD 的中心连锁纵向外周生物标志物
- 批准号:
10555723 - 财政年份:2023
- 资助金额:
$ 49.11万 - 项目类别: